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Abstract
Helicobacter bilis–infected Smad3−/− mice represent an attractive model of inflammation-associated colon cancer.
Most infected mice develop mucinous adenocarcinoma (MUC) by 6 weeks post inoculation (PI); however, approxi-
mately one third do not progress to MUC. The ability to predict the development of MUC in mice used in therapeutic
studies would confer a considerable saving of time and money. In addition, the inadvertent use of mice without MUC
may confound therapeutic studies by making treatments seem falsely efficacious. We assessed both magnetic reso-
nance imaging (MRI) and fecal biomarkers in Helicobacter- and sham-inoculated mice as methods of noninvasively
detecting MUC before the predicted onset of disease. Non–contrast-enhanced MRI was able to detect lesions in
58% of mice with histologically confirmed MUC; however, serial imaging sessions produced inconsistent results.
MRI was also a labor- and time-intensive technique requiring anesthesia. Alternatively, inflammatory biomarkers iso-
lated from feces at early time points were correlated to later histologic lesions. Fecal expression of interleukin 1β,
macrophage inflammatory protein 1α, and regulated on activation, normal T-cell expressed, and secreted at 3 weeks
PI correlated significantly with lesion severity at 9 weeks PI. For each biomarker, receiver-operator characteristic
curves were also generated, and all three biomarkers performed well at 1 to 3 weeks PI, indicating that the develop-
ment of MUC can be predicted based on the early expression of certain inflammatory mediators in feces.
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Abbreviations: AUC, area under the curve: an overall indication of the diagnostic accuracy of a receiver-operator characteristic curve; CRC, colorectal cancer: a malignant neoplastic
disease of the colon and/or rectum; HPRT, hypoxanthine guanine phosphoribosyltransferase: a constitutively produced enzyme involved in purine metabolism used to normalize the
expression of other inducible proteins in polymerase chain reaction assays; IL-1β, interleukin 1β: a pleiotropic inflammatory cytokine produced by antigen-presenting cells and
epithelial cells; MCP-2, monocyte chemotactic protein 2: a CC-type chemokine (CCL8) involved in mixed leukocyte recruitment and activation; MIP-1α, macrophage inflammatory
protein 1: a CC-type chemokine (CCL3) involved in mixed leukocyte recruitment and activation; MUC, mucinous adenocarcinoma: a malignant growth of glandular epithelium
retaining a glandular growth pattern microscopically, and producing significant amounts of mucin, accounting for approximately 11 to 15% of human colorectal adenocarcinoma; PI,
post inoculation; RANTES, regulated on activation, normal T-cell expressed, and secreted: a CC-type chemokine (CCL5) involved in mixed leukocyte recruitment and activation;
ROC, receiver-operator characteristic: a plot of the true-positive rate (sensitivity) against the false-positive rate (1 − specificity) for the different possible cutoff points of a diagnostic test;
RT-PCR, reverse transcription–polymerase chain reaction: a variant of polymerase chain reaction used to amplify complementary DNA, which is initially generated from RNA using
the enzyme reverse transcriptase; SROC, Spearman rank order correlation: a nonparametric measure of statistical dependence between two variables
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Introduction
Colorectal cancer (CRC) is the second leading cause of cancer mortality
in the United States, and the third most common type of cancer in
men and women [1]. Along with certain hereditary conditions, inflam-
matory bowel disease (IBD) ranks as one of the top three high-risk con-
ditions for CRC [2]. For IBD-associated CRC, there is no well-defined
genetic cause, and CRC is thought to develop from a hyperplastic or
dysplastic precursor lesion as a sequela to chronic inflammation.
Classically, the stage of disease at diagnosis, as established by Dukes
in 1932 [3], provides a prognostic indicator of survival [4] because re-
section before lymph node metastasis is often curative. Alternatively,
diagnosis of CRC using Dukes’ stage C or higher, indicating lymph node
metastasis, is associated with poor 5-year survival rates, demonstrating
the necessity of early detection. Currently, the most commonly used
screening techniques are fecal occult blood testing (FOBT), sigmoido-
scopy, colonoscopy, and computed tomographic (CT) colonography
(often called virtual colonoscopy), all of which possess both advantages
and disadvantages. FOBT is affordable and noninvasive, but it fails to
detect most early precancerous polyps and some cancerous lesions in
humans [5,6]. The endoscopic techniques can be used to biopsy or
completely remove potential lesions at the time of the procedure;
however, they require cleansing of the colon, sedation in the case of
colonoscopy, and there is an inherent risk, albeit minimal, of damage
to the mucosa. In addition, sigmoidoscopy is unable to detect lesions
in the proximal colon [7]. CT colonography also requires cleansing of
the colon. Mouse models of CRC are posed with similar challenges, par-
ticularly in the setting of therapeutic studies. As in humans, FOBT test-
ing is limited by the same lack of robust sensitivity and specificity, and
although colonoscopy is possible in mice [8,9], it is both time- and cost-
intensive and requires anesthesia and substantial expertise.
Helicobacter-infected Smad3 knockout mice represent an attrac-
tive animal model for the study of CRC. Mice deficient in Smad3,
a transcription factor downstream of the anti-inflammatory and pro-
apoptotic cytokine transforming growth factor β, develop only a few
mild phenotypic abnormalities including megaesophagus and, at a very
low incidence, angular limb deformities [10] when raised in specific
pathogen-free conditions. However, when infected with enterohepatic
species of Helicobacter, e.g., Helicobacter bilis or Helicobacter hepaticus
[11], approximately two-thirds of these mice develop mucinous adeno-
carcinoma (MUC) of the proximal colon by as early as 6 weeks post in-
oculation (PI).H. bilis andH. hepaticus induce intestinal inflammation in
susceptible strains ofmice [12,13], and the neoplasia seen inHelicobacter-
infected Smad3−/− mice is considered a postinflammatory phenomenon
[11]. In addition, loss of normal transforming growth factor β signaling is
widely recognized as an indicator of malignancy in humanCRC [14,15].
Thus, the targeted deletion of Smad3 in mice is a biologically relevant
model of the human condition.
This model is ideal for therapeutic studies of CRC in that most mice
develop disease on a predicted time course. Moreover, cancer develops
in its natural setting as opposed to the more commonly used models
that use flank injections of immunocompromised mice with human
cancer cell lines. To enhance the usefulness of this model, it would be
ideal to be able to identify CRC at early stages of disease or even before
disease onset. This would allow for both the elimination of mice from
expensive therapeutic studies as well as the assessment of therapeutics
at various stages of disease. For the purposes of evaluating therapeutic
compounds for the treatment of CRC, we endeavored to establish a
method of screening H. bilis–infected Smad3−/− mice before the time
at which disease typically occurs. Our goal was to refine this mouse
model of CRC in an effort to reduce animal numbers and the associ-
ated costs and to increase the power of the data generated in these trials.
Toward these ends, we evaluated both magnetic resonance imaging
(MRI) and several fecal RNA biomarkers as means of detecting dis-
ease and predicting disease severity in H. bilis– and sham-inoculated
Smad3−/− mice in two separate, sequential longitudinal studies using
different cohorts of mice. MRI was selected, as opposed to CT, based
on the greater soft tissue definition afforded by this modality. Non–
contrast-enhanced MRI was able to detect MUC lesions beginning
at 8 weeks PI, and 58% of mice with histologically confirmed lesions
were correctly identified at 16weeks PI.However, serial images produced
inconsistent results. In addition, MRI requires considerable resources to
perform, and image interpretation is inherently subjective and requires
expertise. Alternatively, fecal expression of messenger RNA (mRNA)
specific for interleukin 1β (IL-1β), macrophage inflammatory protein
1α (MIP-1α), and regulated on activation, normal T-cell expressed,
and secreted (RANTES) at 3 weeks PI correlated significantly with
MUC lesion severity at 9 weeks PI in H. bilis–infected Smad3−/− mice,




A H. bilis isolate was obtained from an endemically infected mouse
colony using a previously described culture technique [16]. The isolate
was identified as H. bilis based on ultrastructural morphology, bio-
chemical characteristics, and sequence analysis of the 16S ribosomal
RNA gene [17]. For inoculation, H. bilis cultures were grown in
5 ml of Brucella broth (Becton Dickinson, Franklin Lakes, NJ) sup-
plemented with 5% fetal calf serum (Sigma-Aldrich Co, St Louis,
MO) and overlaid on blood agar plates and incubated for 24 to
48 hours at 37°C in a microaerobic environment containing 90% N2,
5% H2, and 5% CO2.
Animals
All studies were performed in accordance with the Guide for the
Care and Use of Laboratory Animals and were approved by the Uni-
versity of Missouri Institutional Animal Care and Use Committee.
129-Smad3tm/Par/J (referred to as Smad3−/−) mice were bred on site for
these studies. Mice were confirmed to be free of adventitious viruses,
parasites, and pathogenic enteric and respiratory bacteria, including all
known murine Helicobacter spp. Three- to four-week-old Smad3−/−
mice were inoculated twice, 24 hours apart, with 108 H. bilis organisms
in 0.5 ml of Brucella broth, or an equivalent volume of sterile broth,
through gastric gavage. Separate cohorts of mice were used for each study
including incidence of CRC (n = 5-9 mice per time point; Figures 1 and
2), MRI (n = 6 of each sex infected with H. bilis and n = 1 of each sex
sham-infected; Figure 3), 9 weeks PI fecal mRNA levels (n = 7 H. bilis–
infected and 9 sham-infected; Figure 4), and 1 to 7 weeks PI fecal mRNA
levels (n = 14 of H. bilis–infected and n = 9 of sham-infected; Figures 5
and 6). Mice were group-housed according to infection status in auto-
claved microisolator cages and were provided autoclaved food and water.
All manipulations and sample collections were performed in a biosafety
hood except for MRI. Mice were killed at 16 or 9 weeks PI for the
MRI and fecal biomarker studies, respectively, through inhaled over-
dose of CO2.
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Magnetic Resonance Imaging
MRI was performed at 3, 5, 8, 10, 12, 14, and 16 weeks PI using
a 7 T/210 mm Varian Unity Inova MRI system equipped with a
quadrature-driven birdcage coil (38-mm ID; Varian, Inc, Palo Alto,
CA). Mice were anesthetized with 1% to 2% isoflurane in oxygen
through a nose cone. A respiratory sensor was placed on the abdomen
for monitoring of vital signs; body temperature was supported with
warm air circulating in the magnet bore (SA Instruments, Inc, Stony
Brook, NY). Coronal and axial planes were collected using a spin-echo
T1-weighted imaging sequence with a fat saturation pulse applied to
suppress the strong signals from fatty tissues. Typically, images were
collected with 21 slices, 0.8-mm slice thickness, pixel resolution of
59 mm × 127 mm (coronal planes) and 59mm × 59mm (axial planes),
and four scans to average the motion artifacts. Images were processed
using VnmrJ (Varian, Inc, CA).
Sample Collection and Experimental Design
For collection of fecal samples, mice were individually placed in
autoclaved cages containing no bedding within a biosafety hood. Fecal
pellets were collected at 1, 3, 5, 7, and 9 weeks PI with a sterile tuber-
culin syringe and placed in 200 μl of RNAlater (Ambion, Austin, TX)
for isolation of RNA. Pellets in RNAlater were homogenized with a
TissueLyser (Qiagen, Inc, Valencia, CA), centrifuged briefly (Marathon
16 km; Fisher Scientific, Pittsburgh, PA), and then vortexed to re-
suspend fecal material. After euthanasia, the intestinal tract from ileum
to rectum was collected and fixed in formalin.
Histopathology and Ranking of Lesions
Formalin-fixed tissues from H. bilis– and sham-infected mice were
embedded in paraffin, cut in 5-μm-thick sections, and processed for
staining with hematoxylin and eosin. CRC lesions in H. bilis–infected
mice were ranked in a blinded fashion by two laboratory animal pa-
thologists (A.E. and C.F.) according to lesion severity, based on the
number of lesions, the longitudinal and vertical extent of neoplastic
lesions, and the degree of associated inflammation. Rankings were
compared, and in the case of discrepancies in ranking, pathologists con-
ferred and agreed on a rank order.
RNA Extraction from Feces
Total RNA was extracted using the RNeasy Mini Kit respectively,
according to the manufacturer’s protocols (Qiagen). RNAwas quantified
Figure 1. Typical gross (A) and histologic (B-D) appearance of mucinous adenocarcinoma of the proximal colon in H. bilis–infected
Smad3−/− mice at 9 weeks PI demonstrating the prominent mucin lakes (arrowheads) and tumor-associated inflammatory infiltrates
(arrows); images taken at ×100 (B, C) and ×200 (D) of hematoxylin and eosin–stained tissue sections.
Figure 2. Incidence of neoplasia and hyperplasia in Smad3−/−
mice at increasing duration of infection with H. bilis as determined
by histopathologic analysis.
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by measuring the absorbance at 260 and 280 nm using a Nanodrop-
1000 spectrophotometer (Nanodrop, Wilmington, DE).
Reverse Transcription
Five micrograms of total RNA was reverse-transcribed using reverse
transcriptase and oligo(dT) primers according to the manufacturer’s
protocol (SuperScript First-Strand; Invitrogen, Carlsbad, CA). cDNA
was diluted 1:1 with diethylpyrocarbonate-treated water.
Semiquantitative Real-time Reverse Transcription–Polymerase
Chain Reaction
Semiquantitative real-time reverse transcription–polymerase chain re-
action (RT-PCR) was used tomeasuremRNA levels in feces (LightCycler
1.5; Roche Diagnostic, Nutley, NJ). PCRs and melting curves were
performed in a 20-μl volume in glass capillaries containing 0.5 μM of
each primer, 3 mM MgCl2, QuantiTect SYBR Green PCR Master
Mix (Qiagen), and cDNA. To quantify the number of copies of spe-
cific cDNA, a standard curve was created using known concentrations
(101 to 106 copies) of the pCR4-TOPO (Invitrogen) plasmid con-
taining the transcript of interest. PCRs were incubated at 95°C for
15 minutes to activate the polymerase followed by 40 cycles consisting
of a 15-second denaturing at 94°C, 20-second annealing (see Table 1
for primer-specific annealing temperature), and a 30-second extension
at 72°C. The ramp rate was 3°C/sec for annealing and 20°C/sec for
all other steps. Fluorescence was monitored at the end of each exten-
sion phase. After amplification, melting curves were generated to con-
firm PCR product identity.
Primer Sequences and Plasmids
The sequences for hypoxanthine guanine phosphoribosyltransferase
(HPRT) [18], IL-1β [19], monocyte chemotactic protein 2 (MCP-2)
[20], and MIP-1α [21] have been previously reported in the literature.
The primer sequence for RANTESwas designed from publishedmRNA
sequences using DSGene software (Accelrys, San Diego, CA). Standards
were generated using linearized plasmids containing cloned amplicons
of selected targets using the Topo TA PCR cloning kit (Invitrogen).
Transcripts were quantified by comparing fluorescence of experimental
samples to that of plasmid standards containing known concentrations
of the cloned product.
Statistical Analyses
Semiquantitative real-time RT-PCR. Semiquantitative real-time
RT-PCR was used to measure mRNA levels in feces. The expressions
of IL-1β, MIP-1α, MCP-2, and RANTES were normalized to the
expression of the housekeeping gene HPRT. The significance of differ-
ences in normalized expression levels between H. bilis–infected (n = 7)
and sham-infected (n = 9) Smad3−/−mice at 9 weeks PI was determined
Figure 3. Appearance of mucinous adenocarcinoma in situ; outlined (A) and MRI axial images (B) and consecutive micro-MRI coronal
images (C) of a male mouse at 16 weeks PI, demonstrating the corresponding lesion (arrows, B, C) and background signal mimicking
lesions (arrowhead, B). b indicates bladder.
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using the Mann-Whitney rank sum test. The significance of differences
between H. bilis–infected MUC+ (n = 11), H. bilis–infected MUC−
(n = 3), and sham-infected mice (n = 9) at 1 to 7 weeks PI was deter-
mined using the Kruskal-Wallis one-way analysis of variance on ranks
and Dunn’s method of multiple pairwise comparisons.
Correlation to lesion ranks. Coli were evaluated histologically and
ranked according to lesion severity. Rank order of lesion severity in
H. bilis–infected Smad3−/− mice was correlated to the rank order of
normalized expression of each biomarker using Spearman rank order
correlation (SROC).
Receiver-operator characteristic curves. On the basis of the pres-
ence or absence of CRC on histologic interpretation, receiver-operator
characteristic (ROC) curves were generated from H. bilis–infected (n =
14) Smad3−/− mice using the statistical software package SigmaPlot
(SPSS, Chicago, IL). R software [22] was used to compute the con-
fidence intervals (CIs) for the area under the curve (AUC) based on
DeLong’s method [26] as well as to compare ROC curves to each other
based on the Hanley and McNeil method [27]. For CIs for the AUC,
upper limits were truncated at unity.
Results
Progression of Colon Cancer in Smad3−/− Mice
Smad3−/− mice on a 129/Sv background develop colonic neoplasia,
but this phenotype is dependent on infection with either H. bilis or
H. hepaticus, with tumors developing most often in the proximal colon
[11,25]. In the present study, the tumors were typically single masses,
although less than 10% developed a second mass at other sites in the
colon. Grossly, tumors appeared either as a thickened pale area of the
proximal colon or as pearlescent, lobulated, exophytic masses reflecting
the abundant mucin production seen in most masses (Figure 1A).
Histologically, these tumors were best classified as MUC, with an ap-
pearance similar to that seen in humans. Tumors were characterized by
marked goblet and epithelial cell hyperplasia with extensive production
of mucus, often seen sequestered in large dilated “mucin lakes,” spilling
into the lumen of the gastrointestinal (GI) tract or penetrating the
serosal surface and spilling into the peritoneal space. In the latter case,
peritonitis was not uncommon. Many of the neoplastic epithelial cells
retained a simple tall columnar morphology with centrally located,
oblong nuclei containing a vesicular chromatin pattern. There were also
abundant goblet cells, often approaching a 1:1 ratio with columnar
epithelial cells. Surrounding the accumulations of mucinous material,
the epithelium was variably attenuated, and sloughed epithelial and
inflammatory cells were seen in the mucinous material, which was char-
acterized by a lightly basophilic, homogenous to lacy appearance (Fig-
ure 1, B-D). There were also mild to moderate mixed inflammatory
infiltrates in the areas around the tumor. Mitotic figures ranged from
0 to 4, with an average of 1 per high-power field (×400). In the absence
of Helicobacter infection, Smad3−/− mice did not develop MUC or any
detectable intestinal inflammation.
Incidence of MUC in Smad3−/− Mice
To determine whether the incidence of MUCwould increase with in-
creasing duration of infection, Smad3−/−mice orally infectedwithH. bilis
Figure 4.Measurement of IL-1β (A), MIP-1α (B), RANTES (C), and MCP-2 (D) in the feces of Smad3−/−mice at 9 weeks PI as determined
by semiquantitative real-time RT-PCR. Data are reported as the mean number of gene transcripts of interest relative to HPRT. Bars, mean
and SEM. Statistically significant (P < .05) differences between groups are denoted by an asterisk; Mann-Whitney rank sum test.
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were killed at multiple time points after infection, and the GI tract was
collected for histologic examination. Tissues were nominally classified as
being neoplastic (possessing a characteristic MUC lesion), hyperplastic
(showing evidence of focal or diffuse epithelial hyperplasia but not neo-
plasia), or lesion-free. Whereas 100% of mice (5/5) examined at 9 weeks
PI had developed characteristic MUC lesions, only 40% of mice (2/5) at
11 weeks PI and 88% of mice (7/8) at 13 weeks PI showed histologic
evidence of neoplasia (Figure 2). This was not a function of the early
time point because similar results were obtained with mice at 20 weeks
PI (data not shown). Thus, whereas most mice developed identifiable
MUC by as early as 6 weeks PI, not all mice progressed to MUC regard-
less of the duration of infection.
MRI Detection of MUC in Smad3−/− Mice
H. bilis–infected Smad3−/− mice (n = 12, 6 males and 6 females) and
naive wild-type mice of the same background strain (1 male and 1 fe-
male) were imaged using MRI without contrast at 3, 5, 8, 10, 12, 14,
Figure 5. Measurement of IL-1β (A), MIP-1α (B), and RANTES (C) in the feces of Smad3−/− mice from 1 to 7 weeks PI as determined by
real-time RT-PCR. Data are reported as the mean number of gene transcripts of interest relative to HPRT. Error bars, SEM. Statistically
significant (P < .05) differences between groups are denoted by an asterisk; Mann-Whitney rank sum test.
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and 16 weeks PI. Immediately after the final imaging, mice were killed
and carefully dissected and photographed without disturbing the po-
sition of abdominal contents in situ. Gross findings were then com-
pared with the 16-week PI images to assess the capacity of MRI to
detect intestinal lesions and to evaluate the level of background signal
in control mice. The earliest time point at which Helicobacter-infected
mice were interpreted as possessing a neoplastic lesion was 8 weeks
PI. Although we were able to identify a reasonable agreement between
Table 1. Sense and Antisense Primer Pairs Used for Semiquantitative Real-time RT-PCR Amplification.
Gene Name Sense (5′-3′) Antisense (3′-5′) Fragment Size (bp) Annealing Temperature (°C)
HPRT GTAATGATCAGTCAACGGGGGAC CCAGCAAGCTTGCAACCTTAACA 177 60
IL-1β AGCCCATCCTCTGTGACTCATG GCTGATGTACCAGTTGGGGAAC 420 57
MCP-2 ACTAAAGCTGAAGATCCCCCTTCG ACATCACCTGCTTGGTCTGGAAAA 100 57
MIP-1α GCTCAACATCATGAAGGTCTCC TGCCGGTTTCTCTTAGTCAGG 222 57
RANTES GAGTATTTCTACACCAGCAGC GGACTAGAGCAAGCAATGC 192 60
Figure 6. ROC curves for fecal mRNA levels of IL-1β (A, D, G), MIP-1α (B, E, H), and RANTES (C, F, I) at 1 week (A, B, C), 3 weeks (D, E, F),
and 5 weeks (G, H, I) PI in the feces of H. bilis–infected Smad3−/− mice.
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the final (16 weeks PI) images and gross necropsy findings in 7 of 12
H. bilis–infectedmice (sensitivity = 58.33%; Figure 3), 5 of 12mice with
histologically identifiable MUC were interpreted as MUC-negative at
16 weeks PI.
Fecal Cytokine Gene Expression as a Biomarker of MUC at
9 Weeks PI in H. bilis–Infected Smad3−/− Mice
At 9 weeks PI,H. bilis–infected Smad3−/−mice expressed significantly
higher levels of IL-1β (P = .001,Mann-Whitney rank sum test),MIP-1α
(P = .004), and RANTES (P = .003; Figure 4, A-C). However, no dif-
ference was detected in the expression of MCP-2 despite a trend toward
an elevated expression inH. bilis–infected mice (Figure 4D). Two sham-
inoculated mice expressed levels of MCP-2 comparable to even the
highest-expressing H. bilis–infected mice; thus, MCP-2 was eliminated
from further experiments. In this cohort of mice, all seven Helicobacter-
infected mice developed histologically identifiable MUC. SROC was
then performed to correlate the expression of IL-1β, MIP-1α, and
RANTES with lesion severity in the H. bilis–infected mice. Correlation
coefficients for IL-1β, MIP-1α, and RANTES were 0.929 (P < .001),
0.536 (P = .18), and 0.750 (P = .04), respectively, indicating a significant
correlation between lesion scores and expression of both IL-1β and
RANTES. On the basis of the significant overall difference in expres-
sion between infected and control mice in MIP-1α expression, along
with the fact that the two mice with the lowest MIP-1α mRNA levels
also demonstrated the lowest lesion scores, we opted to retainMIP-1α in
subsequent studies. In addition, the kinetics of chemokine and cytokine
expression vary, and we reasoned that, at earlier time points, MIP-1α
might still prove to be a useful biomarker, despite poor overall correlation
at 9 weeks PI.
Fecal Cytokine Gene Expression during the Progression of
MUC in H. bilis–Infected Smad3−/− Mice
To determine whether fecal mRNA levels of IL-1β, MIP-1α, and
RANTES at time points earlier than 9weeks PI could predict subsequent
disease occurrence or severity,mice were inoculated as beforewithH. bilis
(n = 14) or sterile broth (n = 9), and fecal samples were collected every
2 weeks starting at 1 week PI and continuing until 7 weeks PI. Mice
were killed at 9 weeks PI, and tissues were collected for histologic ex-
amination. The normalized expression of each biomarker was de-
termined at each time point, revealing similar kinetics for all three
biomarkers (Figure 5). The expression of all three biomarkers peaked
at 1 week PI and then steadily declined thereafter in Helicobacter-
infected mice. Nonetheless, even at 7 weeks PI, there was a significant
difference (Mann-Whitney rank sum test, P < .05) between H. bilis–
infected MUC+ and sham-infected mice for all three biomarkers.
To assess the value of each biomarker and determine the optimal
screening paradigm, the expression at each time point was correlated
to lesion rank at 9 weeks PI using SROC. In addition, ROC curves
were generated to establish sensitivity, specificity, and appropriate cutoff
values for each biomarker. SROC analysis of samples from 1 to 7 weeks
PI revealed a significant correlation (P < .05) between lesion severity at
9 weeks PI and expression of IL-1β at 1, 3, and 5 weeks PI, of MIP-1α
at 3 and 5 weeks PI, and of RANTES at 3 weeks PI, indicating that
3 weeks PI may be the optimal time for testing mice. Surprisingly,
the correlation between lesion rank and the expression of all three bio-
markers was not statistically significant at 7 weeks PI. However, SROC
indicates the overall agreement between lesions and the selected bio-
markers across the entire range of lesion severity. Because our goal
was to identify “poor responders” and eliminate mice at the low end
of the disease spectrum, ROC curves at each time point were compared
with determine whether very high specificity (>0.98) and acceptable
sensitivity (>0.80) could be achieved simultaneously. Considering the
poor correlation for all markers at 7 weeks PI, empirical ROC curves
were produced for only 1, 3, and 5 weeks PI (Figure 6). CIs were
established using the method of DeLong et al. [26], and the upper limit
was truncated at 1 because AUC values, by definition, cannot exceed
unity. All three biomarkers examined provided an estimated AUC of
0.97 at 3 weeks PI (Figure 6, D-F ; 95% CI = 0.89-1). At 5 weeks
PI, however, fecal mRNA levels of IL-1β yielded an estimated AUC
of 1, thus providing, in this sample, perfect sensitivity and specificity
in predicting the presence or absence of MUC in mice at 9 weeks PI
(Figure 6G ). However, ranking the relative performance of IL-1β at
5 weeks PI and IL-1β, MIP-1α, or RANTES at 3 weeks PI is difficult
because the small sample size gives limited power to discern differences
in AUC; not surprisingly, none of the markers shown in Figure 6 were
statistically different from each other (smallest P = .1), using themethod
of Hanley and McNeil [27]. Because the goal of this study was to es-
tablish a screening method with the ability to predict which mice would
not develop CRC as a means of conserving resources, it should be
noted that by as early as 1 week PI, IL-1β provided an AUC of 0.97
(95% CI = 0.89-1), the same as all three biomarkers at 3 weeks PI. In
addition, the overall correlation between lesion severity rank at 9 weeks
PI and fecal mRNA levels of IL-1β at 1 week PI was 0.65 (P = .01;
SROC). Thus, we propose that in thismodel ofMUC,RT-PCR analysis
of fecal mRNA specific for IL-1β at 1 week PI or of IL-1β, MIP-1α, or
RANTES at 3 weeks PI is a reliable, noninvasive determinant of which
mice will not progress toMUC.More importantly, this provides a proof
of principle that fecal nucleic acid analysis has utility in mouse models
of gastrointestinal neoplasia, as a means of reducing the number of ani-
mals used in study. This may also portend novel screening methods of
interest to the human population.
Discussion
The World Health Organization defines MUC in humans as a tumor
with more than 50% showing a mucinous pattern on histologic exami-
nation and with a large amount of extracellular mucin produced by
secreting acini [28]. Of CRC, MUC accounts for between 11% and
15% [29].Helicobacter-infected Smad3−/− mice recapitulate the human
condition faithfully, with extensive mucin production seen multifocally
in neoplastic foci, forming dilated pockets of mucinous material ex-
tending into the lumen and frequently through the tunica muscularis
to the serosal surface of the GI tract. There are several reasons to believe
that the mechanisms leading to MUC in humans and Helicobacter-
infected Smad3−/−mice are similar. In humans, as inHelicobacter-infected
Smad3−/− mice, MUC occurs more frequently in the proximal colon
than elsewhere in the GI tract [30–32]. Although not all studies agree,
possibly due to geographical differences [33] or the presence of two
subtypes of colorectal MUC [30], MUC in humans seems to be more
prevalent as a sequela to IBD than as a spontaneous CRC not associated
with previous IBD [32,34–37]. Supporting this concept, MUC occurs
primarily in areas of chronic inflammation, and the risk of MUC in-
creases with duration of IBD [38,39]. Similarly, the findings detailed
herein support the notion that the severity of MUC in Helicobacter-
infected Smad3−/− mice is largely dependent on the robustness of the
inflammatory response to a member of the gut flora, as measured by
the expression of certain fecal cytokines and chemokines. In addi-
tion, MUC in humans is frequently associated with fistula formation
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[32,35,40–43], a phenomenon attributed to adenomatous transforma-
tion of the epithelium lining the fistula tract [44]. ManyH. bilis–infected
Smad3−/− mice showed histologic evidence of perforation of the bowel
wall and areas in which dysplastic epithelial cells are seen invading
and penetrating the serosal surface (Figure 1, B-D), and it is tempting
to speculate that a similar mechanism is at work in the formation of
MUC lesions in Smad3−/− mice.
Regardless of the pathogenesis, not all Smad3−/− mice will develop
MUC despite persistent colonization with H. bilis. As a consequence,
many of these MUC-resistant mice will be used in expensive thera-
peutic trials lasting up to 8 months in duration. Along with the time
and money spent maintaining mice that will not progress to MUC,
one must also consider that these mice are potentially confounding
the research by making therapeutic compounds seem falsely efficacious.
The ability to noninvasively identify which mice will not progress to
cancer would both conserve resources and increase the power of data
generated by using only mice with a high probability of developing
MUC. We first evaluated MRI as a means of detecting early inflamma-
tory or precancerous lesions in Helicobacter-infected Smad3−/− mice.
Mice were imaged every 2 to 3 weeks until 16 weeks PI, a time by which
previous studies (Figure 2) had demonstrated most mice would develop
MUC. Although MRI provided some diagnostic information, that is,
the presence or absence of a lesion, it afforded little prognostic infor-
mation regarding the severity or extent of disease at necropsy when
images were analyzed retrospectively. This is partially due to the vari-
ability between images from week to week. Frequently, MRI would
indicate a possible lesion at one time point, followed by images at sub-
sequent time points interpreted as negative. In only 1 of 12 mice did
images consistently contain suspect lesions after the initial appearance.
In addition, in those mice in which a correlation between 16-week PI
MRI images and gross lesions was detected, it was difficult to reliably
track the course of intestinal neoplasms retrospectively. The background
noise, seen in both experimental and control mice, was considerable
and was most problematic in highly glandular tissue such as the repro-
ductive tract. In addition, the severity of the lesions could not be pre-
dicted based on the size and intensity of suspect lesions on MRI. Mice
with hyperintense signal on the final imaging, indicating a large or se-
vere lesion, often revealed mild or moderate MUC lesions at necropsy.
Conversely, mice with borderline “positive” final images often revealed
extensive markedMUC or even multiple lesions. MRI has been applied
to the human population as a screening method for MUC; however,
the method requires insufflation of the colon with air to enhance im-
aging [1]. The lack of insufflation in our study may partially explain
the lack of adequate definitionwithMRI. Also, the imaging in this study
was performed without the use of contrast. MRI studies of the gastro-
intestinal tract using a fecal-tagging based MRI contrast agent may en-
hance visualization of MUC lesions [45]. The primary goal of these
studies was to evaluate two distinct methods of detecting CRC in a
mouse model, noninvasively and as early in the disease process as pos-
sible. Because our motivation was to conserve resources, we opted to
omit insufflation and contrast in an effort to keep the procedure as sim-
ple and cost-effective as possible. In our study, a mass showing hyper-
intense and heterogeneous signal contents would indicate aMUC lesion
(Figure 3, B and C). However, abdominal motion artifacts and signifi-
cant signals from feces often cause ambiguities or missed detections.
A respiratory-gated T2-weighted MRI protocol may be applied to in-
crease the detection accuracy and specificity for MUC because of the
brighter signal nature of mucin contents inMUC lesions on T2-weighted
images, however, with the expense of prolonged imaging time. Lastly,
considering the expense of the initial purchase, maintenance, and opera-
tion, MRI is a costly technique for screening large numbers of animals.
Imaging in both coronal and axial planes resulted in 21 and 42 images,
respectively, per mouse at each time point, which, along with the user-
dependent nature of image interpretation, made this a time-consuming
and subjective technique. Because our impetus for screening animals is
to eliminate mice that are not going to develop MUC as a means of
saving costs, MRI is problematic. Thus, the inability of MRI to detect
disease in a reproducible manner, the associated costs, and the labor-
intensive and subjective nature of this method make it less than ideal
for our purposes.
Next, we elected to determine whether CRC in our model could be
predicted through the analysis of fecal cytokine and chemokine mes-
sage levels. This concept, although not new in humans [46,47], has
not been applied to murine models to the authors’ knowledge. Because
humans and mice both constitutively slough colonic epithelial cells in
feces, the RNA isolated from these cells should reflect the state of
health or inflammation present in the gut. Inflammation is now rec-
ognized as a risk factor and negative prognostic indicator for certain
types of neoplasia in humans [48]. Adaptive antitumoral immune re-
sponses, particularly those mediated by CD8+ T cells, are considered
protective and beneficial in destroying tumor cells, whereas inflam-
mation due to innate immune responses is often associated with a poor
prognosis [49]. This concept can be extrapolated to the chemokines
responsible for attracting T cells or macrophages; accumulation of
lymphocytes due to increased expression of CXCL16 correlates with
a favorable outcome in human CRC [50], whereas accumulation of
tumor-associated macrophages due to increased levels of CCL2 cor-
relates with poor outcome [51]. Thus, as a means of noninvasively
assessing the degree of colonic inflammation in Smad3−/− mice, we
measured the fecal levels of several factors involved in macrophage
recruitment, and which have been shown to be elevated in human
CRC [49,52,53], including the chemokines MIP-1α, RANTES, and
MCP-2 and IL-1β, a highly pleiotropic proinflammatory cytokine with
effects on virtually all cell types [54]. Our initial fecal biomarker study
was performed at 9 weeks PI, when most mice were expected to have
developed MUC. It was established that a significant difference in the
fecal expression of IL-1β, MIP-1α, and RANTES existed between
Helicobacter- and sham-infected mice (Figure 4); however, 100% (7/7)
of the infected mice in this group developed MUC, making a com-
parison of MUC+ and MUC− mice within the infected group impos-
sible. Pursuing earlier time points PI (Figure 5) with a second group
of mice provided evidence that there is also a significant difference in
the expression of these biomarkers between H. bilis–infected MUC+
and MUC− mice, supporting their use as predictors of MUC in this
model. It is notable that the expression of IL-1β, MIP-1α, and
RANTES showed an acute increase after infection with Helicobacter,
which waned steadily thereafter. Although these biomarkers are pri-
marily associated with innate immune responses, infection withH. bilis
eventually induces an adaptive immune response [55], allowing the
innate response to wane accordingly. Like the selected chemokines,
IL-1β is produced by the intestinal epithelium. Because intestinal epi-
thelial cells also express the activating receptor IL-1RI [54], IL-1β func-
tions in an autocrine and paracrine manner to amplify chemokine
expression. Similarly, RANTES has been shown to stimulate produc-
tion of MIP-1α by human monocytes [56], suggesting that activation of
tumor-associated macrophages may amplify recruitment of additional
monocytes and other leukocytes, thought to be the source of harmful
reactive oxidative intermediaries. Interestingly, several studies indicate
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that IL-1β may have a more direct role in colorectal tumorigenesis. In
2003, Liu et al. [57] demonstrated that IL-1β upregulates the expression
of cyclooxygenase-2 (COX-2), which is overexpressed in 80% to 90% of
humanCRC [58] and is also found to be elevated inHelicobacter-infected
Smad3 sup>−/− mice relative to naive mice [11]. Similarly, Maihofner
et al. [59] showed that, in both human CRC-associated neoplastic epi-
thelium and tumor-associated macrophages, COX-2 expression was
markedly increased and that increase correlated with increases in IL-1β.
COX-2 functions to facilitate tumor development through the induc-
tion of antiapoptotic and angiogenic factors [60,61], and it is worth
noting that fecal mRNA levels of COX-2 have been evaluated as screen-
ing techniques for human CRC [62,63]. In addition, IL-1β has a potent
proliferative effect on human carcinoma cell lines [64], most likely
through the induction of other growth factors. With regard to the mu-
cinous phenotype seen in Helicobacter-infected Smad3−/− mice, IL-1β
has been shown to upregulate the expression and release of mucins in
both colonic epithelial cell lines [65,66] and perfused rat colon [67].
Regardless of the mechanism, the present data suggest that MUC in
Smad3−/− mice is highly correlated with the previous expression of
IL-1β, MIP-1α, and RANTES.
Until recently, the amplification of nucleic acids from feces has been
hindered by poor recovery because of the presence of nucleases. DNA
is much more stable than RNA and can typically be amplified from
feces that have been snap-frozen in liquid nitrogen. However, because
of the inherent instability of RNA and the abundance of prokaryotic
nucleases in the feces, a preservative containing RNAse inhibitors is
needed to isolate mRNA from feces. When compared with several
other methods of RNA preservation including liquid nitrogen, silica
gel, Whatman FTA cards, and Paxgene, Yu et al. [68] found RNAlater
to provide the optimal quantity and quality of RNA as well as the low-
est level of genomic DNA contamination. For our studies, two fecal
pellets per mouse were collected in 200 μl of RNAlater at each time
point, yielding 600 to 800 ng/μl RNA per sample. Assuming an aver-
age mass of 35 mg per fecal pellet, this results in an average yield of
approximately 70 μg of RNA per gram of feces. An early description
of a similar technique applied to human stool yielded from 5 to 30 μg
of RNA per gram of stool from CRC patients and approximately 5 μg of
RNAper gram fromhealthy controls [46]. Several points should bemade
regarding this difference. An obvious caveat is the different methods
of RNA extraction from feces. Although the present data represent
RNA extracted using a commercially available kit from feces preserved
in RNAlater, the samples from human CRC patients and controls were
snap-frozen in liquid nitrogen, and RNAwas extracted with acid phenol
and chloroform. A second consideration regarding differences in RNA
recovery from mouse and human stool is the fate of senescent epithelial
colonocytes. In humans, effete colonocytes are primarily removed
through mucosal phagocytosis, allowing subcellular components to be
recycled [69]. Alternatively, colonocytes in rodents are lost primarily
through simple exfoliation into the lumen [69]. Thus, it would be ex-
pected that rodent feces would contain more RNA on a per-weight
basis and may be ideally suited to molecular techniques such as those
described here.
There is a strong likelihood that these techniques are applicable to
other mouse models of CRC. One would expect that postinflammatory
models of intestinal neoplasia would be particularly amenable to fecal
cytokine or chemokine analysis. Several other strains of mice used
as models of colitis are also prone to CRC, including IL-10−/− mice
[70], IL-2null × β2mnull mice [71], and Gαi2
−/−mice [72] among others.
In each model, while the development of colitis precedes CRC, sug-
gesting that CRC is driven by the inflammatory response, only 31%
to 60% of mice in these models will progress to carcinoma [37]. Thus,
while the appropriate biomarkers and their kinetics would need to
be established for each model (and possibly laboratory), the concept
of predicting the presence or severity of disease using fecal biomarkers
of inflammation likely applies to more than just the Smad3−/− mouse
model. Similarly, several fecal biomarkers, including RNA specific for
COX-2 and matrix metalloproteinase 7, have garnered interest as screen-
ing tools for CRC in humans [62,63]. As microarray technologies be-
come more commonplace, the use of fecal RNA analysis may allow for
robust, noninvasive CRC screening in humans. Smad3−/− mice offer a
useful tool for these types of studies, and the refinement of the model
described herein will enhance the development of both screening tech-
niques and therapeutic modalities for CRC.
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